R
Robert A Nordal
Researcher at University of Calgary
Publications - 1
Citations - 353
Robert A Nordal is an academic researcher from University of Calgary. The author has contributed to research in topics: Clinical endpoint & Hazard ratio. The author has an hindex of 1, co-authored 1 publications receiving 276 citations.
Papers
More filters
Journal ArticleDOI
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert,Brigitta G. Baumert,Monika E. Hegi,Martin J. van den Bent,Andreas von Deimling,Thierry Gorlia,Khê Hoang-Xuan,Alba A. Brandes,Guy Kantor,Martin J.B. Taphoorn,Mohamed Ben Hassel,Christian Hartmann,Christian Hartmann,Gail Ryan,David Capper,Johan M. Kros,Sebastian Kurscheid,Sebastian Kurscheid,Wolfgang Wick,Roelien H. Enting,Michele Reni,Brian Thiessen,Frédéric Dhermain,Jacoline E C Bromberg,Loïc Feuvret,Jaap C. Reijneveld,Olivier Chinot,J.M.M. Gijtenbeek,John P. Rossiter,Nicolas Dif,Carmen Balana,Jose Bravo-Marques,Paul Clement,Christine Marosi,Tzahala Tzuk-Shina,Robert A Nordal,Jeremy Rees,Denis Lacombe,Warren P. Mason,Roger Stupp,Roger Stupp +40 more
TL;DR: There was no significant difference in outcome of the overall patient population treated with either radiotherapy alone or TMZ chemotherapy alone, and further data maturation is needed for overall survival analyses and evaluation of the full predictive impact of the molecular subtypes for individualized treatment choices.